Cough and cold medications that contain a sympathomimetic decongestant such as phenylephrine should be used cautiously in what population:
Explanation & Rationale
Rationale: A. Older adults often have underlying cardiovascular conditions or benign prostatic hyperplasia, which can be exacerbated by the alpha-adrenergic effects of sympathomimetics. These drugs can cause urinary retention by contracting the smooth muscle of the bladder neck and prostate. Additionally, older patients are more susceptible to the central nervous system side effects of these medications, such as insomnia, restlessness, and increased heart rate. B. Decongestants like phenylephrine have not been proven safe or effective in infants and young children and have been linked to serious adverse events, including seizures and tachycardia. Regulatory agencies like the FDA strongly advise against the use of OTC cough and cold medicines in children under the age of 4. In this vulnerable population, the risk of toxic ingestion or severe physiological reactions significantly outweighs any minor symptomatic relief. C. Sympathomimetics act as systemic vasoconstrictors by stimulating alpha-1 adrenergic receptors on vascular smooth muscle, which directly increases peripheral vascular resistance. In patients with pre-existing hypertension, this can lead to dangerous elevations in blood pressure and increased myocardial oxygen demand. Even in controlled hypertensive patients, these medications can interfere with the efficacy of their antihypertensive therapy and provoke a hypertensive crisis. D. All the listed populations face significant physiological risks from the systemic effects of sympathomimetic decongestants. Whether it is the cardiovascular strain in hypertensive patients and seniors or the lack of safety data in infants, these groups require careful clinical screening. Healthcare providers should prioritize non-pharmacological interventions, such as saline sprays or humidification, for these high-risk individuals to avoid the systemic adverse effects of oral decongestants.